Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 38Lymphoma 38Lung Neoplasms 25Ovarian Neoplasms 24Melanoma 23Neoplasm Metastasis 21Hematologic Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 19Fallopian Tube Neoplasms 19Breast Neoplasms 18Prostatic Neoplasms 17Glioma 17Sarcoma 14Carcinoma, Renal Cell 14Colorectal Neoplasms 13Uterine Cervical Neoplasms 12Lymphoma, Non-Hodgkin 12Urinary Bladder Neoplasms 11Small Cell Lung Carcinoma 11Neoplasms 11Leukemia, Lymphocytic, Chronic, B-Cell 11Glioblastoma 11Triple Negative Breast Neoplasms 10Pancreatic Neoplasms 10Medulloblastoma 10Wilms Tumor 9Sarcoma, Ewing 9Rhabdomyosarcoma 9Rhabdoid Tumor 9

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × NIH × Tumor Virus Infections × Clear all
NCT05797246 2026-05-29

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
21 enrolled

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡